#China #Shanghai #NVIDIA #Drug Discovery #Viva Biotech

Accelerating Drug Discovery with AI

In a strategic move to revolutionize drug discovery, Viva Biotech announced a collaboration with NVIDIA to enhance its drug development platform using artificial intelligence (AI). On March 16, 2026, the company unveiled its innovative approach centered around the Proteina-Complexa model, which aims to optimize the design of mini-binders targeting ActRIIA — a receptor crucial in muscle wasting and maintaining lean mass balance.

This partnership showcases Viva Biotech's commitment to integrating advanced technologies within its 'Lab-in-the-Loop' workflow. The integration of computational designs with high throughput protein production and biophysical evaluation is a game-changer in the quest for new therapeutics. This methodology bridges the gap between computational predictions and experimental validations, thereby accelerating the drug discovery process.

Viva Biotech's AI-driven platform utilizes NVIDIA's BioNeMo technology to enhance the optimization of drug candidates effectively. By leveraging AI for sequence selection, the company has made significant improvements to the original Proteina-Complexa model. With this refined approach, Viva Biotech achieved more targeted designs and increased efficiency in developing mini-binders. The guidance provided by AI insights enabled the exploration of uncharted chemical spaces, representing a substantial breakthrough in specificity.

One of the key advantages of this new model is its cost-effectiveness and time-saving nature, significantly enhancing the conventional drug development timeline. Instead of relying solely on traditional methods, the integration of AI-driven insights has streamlined the design process, allowing for faster responses to emerging health needs.

As a leading contract research organization (CRO) specializing in AI-driven drug discovery, Viva Biotech prides itself on its ability to merge computational modeling with groundbreaking laboratory techniques. The company's portfolio includes a broad spectrum of drug types, such as small molecules, antibodies, peptides, fusion proteins, PROTACs, molecular glues, and RNA-targeting compounds.

Looking ahead, Viva Biotech is poised to continue refining its AI algorithms while further developing its drug discovery capabilities. The potential for groundbreaking advancements in therapeutic solutions is immense, and Viva Biotech aims to position itself at the forefront of the burgeoning AI-driven drug discovery landscape. By continually innovating and optimizing its processes, the company seeks to deliver impactful solutions that meet the evolving needs of its partners in the pharmaceutical and biotechnology sectors.

In conclusion, the collaboration between Viva Biotech and NVIDIA represents a significant stride towards reshaping the future of drug discovery. With AI at the helm, the quest for novel therapeutics becomes more efficient, impactful, and promising than ever. This partnership not only enhances the development of effective treatments but also demonstrates how technology can transform healthcare as we know it.